Literature DB >> 21524318

Crohn's disease.

Sarah C Mills1, Alexander C von Roon, Paris P Tekkis, Timothy R Orchard.   

Abstract

INTRODUCTION: Crohn's disease is a chronic condition of the gastrointestinal tract. It is characterised by transmural, granulomatous inflammation that occurs in a discontinuous pattern, with a tendency to form fistulae. The cause is unknown but may depend on interactions between genetic predisposition, environmental triggers, and mucosal immunity. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of medical treatments to induce remission in adults with Crohn's disease? What are the effects of surgical interventions to induce and maintain remission in adults with small-bowel Crohn's disease? What are the effects of surgical interventions to induce remission in adults with colonic Crohn's disease? What are the effects of medical interventions to maintain remission in adults with Crohn's disease; and to maintain remission following surgery? What are the effects of lifestyle interventions to maintain remission in adults with Crohn's disease? We searched: Medline, Embase, The Cochrane Library, and other important databases up to December 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 93 systematic reviews, RCTs, or observational studies that met our inclusion criteria.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: aminosalicylates, antibiotics, azathioprine/mercaptopurine, ciclosporin, corticosteroids (oral), enteral nutrition, fish oil, infliximab, methotrexate, probiotics, resection, segmental colectomy, smoking cessation, and strictureplasty.

Entities:  

Mesh:

Year:  2011        PMID: 21524318      PMCID: PMC3217808     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  103 in total

Review 1.  Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.

Authors:  W Clark; J Raftery; F Song; P Barton; C Cummins; A Fry-Smith; A Burls
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

Review 2.  Systematic review: has disease outcome in Crohn's disease changed during the last four decades?

Authors:  F L Wolters; M G V M Russel; R W Stockbrügger
Journal:  Aliment Pharmacol Ther       Date:  2004-09-01       Impact factor: 8.171

Review 3.  A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Ali Rezaie; Mohammad Abdollahi
Journal:  Clin Ther       Date:  2006-12       Impact factor: 3.393

Review 4.  Enteral nutritional therapy for induction of remission in Crohn's disease.

Authors:  M Zachos; M Tondeur; A M Griffiths
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

5.  Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.

Authors:  R Caprilli; M Cottone; F Tonelli; G Sturniolo; F Castiglione; V Annese; C Papi; A Viscido; C Cammà; G Corrao; G Latella
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 7.  Short-term outcomes after laparoscopic ileocolic resection for Crohn's disease. A systematic review.

Authors:  Sebastiaan W Polle; Jan Wind; Dirk T Ubbink; Daan W Hommes; Dirk J Gouma; Willem A Bemelman
Journal:  Dig Surg       Date:  2006-12-12       Impact factor: 2.588

8.  A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease.

Authors:  J P Wright; D P Jewell; R Modigliani; H Malchow
Journal:  Inflamm Bowel Dis       Date:  1995       Impact factor: 5.325

9.  Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.

Authors:  Sarah Caspersen; Margarita Elkjaer; Lene Riis; Natalia Pedersen; Christian Mortensen; Tine Jess; Pernille Sarto; Tanja S Hansen; Vibeke Wewer; Flemming Bendtsen; Flemming Moesgaard; Pia Munkholm
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10-09       Impact factor: 11.382

Review 10.  Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.

Authors:  A H Steinhart; A Forbes; E C Mills; B S Rodgers-Gray; S P L Travis
Journal:  Aliment Pharmacol Ther       Date:  2007-06-15       Impact factor: 8.171

View more
  2 in total

Review 1.  Diet Advice for Crohn's Disease: FODMAP and Beyond.

Authors:  Stefan L Popa; Cristina Pop; Dan L Dumitrascu
Journal:  Nutrients       Date:  2020-12-06       Impact factor: 5.717

2.  Dietary Habits of a Group of Children with Crohn's Disease Compared to Healthy Subjects: Assessment of Risk of Nutritional Deficiencies through a Bromatological Analysis.

Authors:  Flavio Labriola; Caterina Marcato; Chiara Zarbo; Ludovica Betti; Arianna Catelli; Maria Chiara Valerii; Enzo Spisni; Patrizia Alvisi
Journal:  Nutrients       Date:  2022-01-24       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.